Meeting
2017 ASCO Annual Meeting
Cost-effectiveness of prophylactic antibiotics to prevent pneumonia in patients treated with chemoradiotherapy (CRT) for locally advanced head and neck carcinoma (LAHNC).
Authors
Janneke Ham
Radboud University Medical Center, Nijmegen, Netherlands
Janneke Ham , Chantal Driessen , Mathijs P Hendriks , W. Edward Fiets , Bas Kreike , Ann Hoeben , Marije Slingerland , Claudia van Opstal , Bart-Jan Kullberg , Eddy MM Adang , Johannes Kaanders , Winette T.A. Van Der Graaf , Carla M.L.- Van Herpen
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Head and Neck Cancer
Track
Head and Neck Cancer
Sub Track
Local-Regional Disease
Clinical Trial Registration Number
NCT01598402
Citation
J Clin Oncol 35, 2017 (suppl; abstr 6075)
DOI
10.1200/JCO.2017.35.15_suppl.6075
Abstract #
6075
Poster Bd #
63
Abstract Disclosures
Similar Posters
Poster
2016 ASCO Annual Meeting
Prophylactic antibiotics to prevent pneumonia in patients treated with chemoradiotherapy (CRT) for locally advanced head and neck carcinoma (LAHNC).
First Author: Janneke Ham
Poster
2024 ASCO Annual Meeting
Cost-effectiveness analysis of contemporary first-line (1L) agents in locally advanced/metastatic urothelial carcinoma (la/mUC).
First Author: Syed Arsalan Ahmed Naqvi
Poster
2024 ASCO Annual Meeting
Effect of nivolumab combined with definitive chemoradiotherapy on response rate for esophageal cancer: An immune active intrinsic subtype could be its biomarker—The NOBEL trial.
First Author: Manabu Muto
Poster
2024 ASCO Annual Meeting
Primary prophylaxis with pegylated-granulocyte colony-stimulating factor for patients with unresectable pancreatic cancer treated with modified-FOLFIRINOX: A randomized phase II trial.
First Author: Choong-kun Lee